QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Partnership combines QIAGEN's QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element's AVITI System users in genomic analysis Element and QIAGEN are advancing genomic applications with innovative technology and complete next-generation sequencing (NGS) workflows for researchers Partnership to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community VENLO, Netherlands, and SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the AVITI™ System, an innovative sequencing platform based on Element's novel Avidity sequencing chemistry. Element's AVITI System, a flexible benchtop sequencer with industry-leading performance and cost, delivers high quality, affordable data for any application, at a range of scale.

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System

Qiagen N.V. (NYSE:QGEN ) Q3 2023 Results Conference Call October 31, 2023 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sackers - CFO Phoebe Loh - IR Conference Call Participants Catherine Schulte - R.

Qiagen N.V. (QGEN) Q3 2023 Earnings Call Transcript

In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say

Qiagen (QGEN) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.53 per share a year ago.

Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates

Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlook for at least $465 million CER and adjusted diluted EPS of $0.50 CER ahead of outlook for at least $0.48 CER // 5% CER sales growth in non-COVID portfolio to $442 million, supported by higher sales from instruments as well as recurring consumables and related revenues // 9M 2023: 8% CER sales growth in non-COVID portfolio, led by 88% highly recurring consumables revenues // Full-year 2023: Outlook reaffirmed for net sales of at least $1.97 billion CER; adj. diluted EPS of at least $2.07 CER Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlook for at least $465 million CER and adjusted diluted EPS of $0.50 CER ahead of outlook for at least $0.48 CER // 5% CER sales growth in non-COVID portfolio to $442 million, supported by higher sales from instruments as well as recurring consumables and related revenues // 9M 2023: 8% CER sales growth in non-COVID portfolio, led by 88% highly recurring consumables revenues // Full-year 2023: Outlook reaffirmed for net sales of at least $1.97 billion CER; adj. diluted EPS of at least $2.07 CER

QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER

Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

QIAGEN N.V. to release results for Q3 2023 and hold webcast

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus' role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus' role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.

QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software

AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN's proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN's proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs

QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness

TUNIS, Tunisia, Sept. 28, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help kidney disease, transplant and dialysis patients – the world's first-ever guidance of this type by a professional body in kidney medicine.

QIAGEN's QuantiFERON solutions recommended for use by kidney specialists in Tunisia

Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance

QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050 New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050

QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits

QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.

QIAGEN's (QGEN) New API Streamlines Access to BKB Data

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?

Qiagen NV (NYSE:QGEN ) Q2 2023 Earnings Conference Call August 9, 2023 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Odysseas Manesiotis - Berenberg Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Group Casey Woodring - JPMorgan Chase & Co. Aisyah Noor - Morgan Stanley Falko Friedrichs - Deutsche Bank Daniel Arias - Stifel, Nicolaus & Company Hugo Solvet - BNP Paribas Exane Operator Ladies and gentlemen, thank you for standing by. I am Katie, your PGI call operator.

Qiagen NV (QGEN) Q2 2023 Earnings Call Transcript

QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.

QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed

Qiagen (QGEN) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.51 per share a year ago.

Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates

Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM business; adj. diluted EPS revised to at least $2.07 CER Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM business; adj. diluted EPS revised to at least $2.07 CER

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

QIAGEN's therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN's leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics QIAGEN's therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN's leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics

News for QIAGEN Stock (QGEN)